Wichtige Mitteilung für unsere Geschäftspartner: Wechsel in der Geschäftsführung der NUKEM Isotopes GmbH
Mit Wirkung zum 01. November 2022 ergibt sich eine Änderung in der Geschäftsführung der NUKEM Isotopes GmbH. Herr Wilhelm Plumpe scheidet aus der Geschäftsführung aus und verabschiedet sich in seinen wohlverdienten Ruhestand. Herr Wilhelm Plumpe war maßgeblich an der Gründung der NUKEM Isotopes GmbH beteiligt und wir bedanken uns für seinen jahrelangen tatkräftigen Einsatz. Darüber hinaus freuen wir uns mitzuteilen, dass wir unseren Hauptgesellschafter Wilhelm Plumpe davon überzeugen konnten, dem Unternehmen im Beirat weiter beratend zur Seite zu stehen.
Per Gesellschafterbeschluss wurden Herr Michael Kievel sowie Herr Daniel Plumpe als neue Geschäftsführer der NUKEM Isotopes GmbH berufen.
Herr Kievel verfügt mit weit über 20 Jahren Berufserfahrung im Bereich der stabilen Isotope über ein sehr starkes Netzwerk in der Branche und betreut bereits seit Gründung der NUKEM Isotopes als Prokurist sowie als Chief Sales Officer unsere Geschäftspartner in allen Belangen.
Herr Daniel Plumpe ist seit April 2020 im Unternehmen. Nach einem betriebswirtschaftlichen Studium sowie jahrelanger Erfahrung in den Bereichen Finanzen und Controlling in verschiedenen Unternehmen unterschiedlicher Branchen liegen seine Schwerpunkte zukünftig auf dem gesamten kaufmännischen Bereich sowie der strategischen Ausrichtung des Unternehmens.
„Mit Stolz und Dankbarkeit blicke ich auf die vergangenen, sehr erfolgreichen Jahre als Geschäftsführer der NUKEM Isotopes GmbH zurück. Es waren fast auf den Tag genau 11 erfüllte Jahre! Vielen Dank dafür.
Jetzt ist es an der Zeit, Jüngeren das Zepter zu übergeben. Mit der Neubesetzung der Geschäftsführung der NUKEM Isotopes GmbH soll unser gemeinsamer Weg, den wir 2011 begonnen haben, weiter erfolgreich beschritten und das Unternehmen weiterentwickelt werden.
Michael Kievel sowie Daniel Plumpe konnten bereits in ihren vorangegangenen Positionen in den letzten Jahren zeigen, dass sie unser Unternehmen erfolgreich vertreten und führen können. In Zeiten von Pandemie und kriegerischen Auseinandersetzungen wurde uns dies sicherlich nicht immer leicht gemacht. Ich bin überzeugt davon, dass auch das neue Management, zusammen mit dem gesamten Team, es schaffen wird, diese Krisen zu bewältigen und NUKEM Isotopes als verlässlicher Partner für unsere Kunden und Lieferanten weiter auf Erfolgskurs zu halten.
Ich möchte mich bei allen Partnern für die gute Zusammenarbeit und das Vertrauen, welches Sie in den vergangenen Jahren in mich und in NUKEM Isotopes gesetzt haben, herzlich bedanken.
Mit den allerbesten Wünschen für eine gemeinsame Zukunft
Important notice to our business partners: Change in the management of NUKEM Isotopes GmbH
As of November 1st, 2022 there will be a change in the management of NUKEM Isotopes GmbH. Mr. Wilhelm Plumpe will resign as the companies CEO and take his well-deserved retirement. He was instrumental in the foundation of NUKEM Isotopes GmbH and we would like to thank Wilhelm for his many years of active commitment. Furthermore, we are pleased to announce that we were able to convince Wilhelm, as the company’s main shareholder, to join the advisory board in future.
By shareholder resolution, Mr. Michael Kievel and Mr. Daniel Plumpe were appointed as the new managing directors of NUKEM Isotopes GmbH.
With more than 20 years of professional experience in the field of stable isotopes, Michael has a very strong network in the industry. Since the foundation of NUKEM Isotopes, he has been supporting our business partners in all matters as authorized signatory and Chief Sales Officer.
Daniel has been with the company since April 2020. After studying business administration and years of experience in the areas of finance and controlling in various companies in different sectors, his future focus will be on the entire commercial area and the strategic orientation of the company.
„I look back with pride and gratitude on the past, very successful years as Managing Director of NUKEM Isotopes GmbH. It has been 11 fulfilling years almost to the day! Many thanks for that.
Now it is time to hand over the baton to younger ones. With the new appointment of the management of NUKEM Isotopes GmbH, our common path, which we started in 2011, shall continue to be successfully followed and the company shall be further developed.
Michael Kievel and Daniel Plumpe have already shown in their previous positions in recent years that they can successfully represent and lead our company. In times of pandemic and armed conflict, this was certainly not always made easy for us. I am convinced that the new management, together with the entire team, will manage to overcome these crises and keep NUKEM Isotopes on the road to success as a reliable partner for our customers and suppliers.
I would like to express my sincere thanks to all partners for the good cooperation and the trust you have placed in me and in NUKEM Isotopes over the past years.
With the very best wishes for a common future
We are proud to announce that will be exhibiting again at this year’s ISMRM in London, UK, May 8th to May 12th, 2022.
We would be pleased if you visit us at booth # D16 to learn more about our products and latest research cooperations.
We are looking forward to meeting you in London.
November 2021 – 10 years anniversary
We are very pleased and proud to announce that we are celebrating our 10th anniversary in November 2021. We would like to thank all our customers, suppliers and all cooperation partners for the fantastic cooperation in the last 10 years. Without you this would not have been possible. We are looking forward to many more successful years and invite you to download our anniversary brochure for free.
June 2020 – Exhibitions and Fairs in Times of Covid-19 – Update –
We are currently in turbulent times and as a matter of fact, an end to the global Covid-19 pandemic is not yet in sight. We at NUKEM Isotopes were looking forward to meeting you, our valued customers, suppliers and partners at our booth at ISMRM and EANM 2020.
We therefore regret very much to inform you that we have decided not to participate as an exhibitor at neither this year’s ISMRM in Paris nor EANM in Vienna. Because we care about your health as well as that of our employees, we decided to take this step.
Since we also value f2f contact with our clients, we also decided not to take part in the virtual exhibition formate.
We sincerely hope that we can meet you all personally and healthily again next year.
In the meantime, if you have any questions about our products or the latest developments, we are of course available to you at any time by email, telephone or video conference.
Stay healthy and take care of yourself.
We look forward to seeing you all in Vancouver, Canada in May 2021.
Until then, Sincerely Your
NUKEM Isotopes team.
Alzenau, Germany – NUKEM Isotopes GmbH is proud to announce and welcome Daniel Plumpe as the new Director of Controlling. Daniel will work closely with the company’s CFO to focus on key economic issues of the business.
Daniel has already gained controlling experience in the field of energy trading. The entire NUKEM Isotopes team is happy to welcome Daniel as a new member of the NUKEM Isotopes family. With his background, he definitely shares our spirit, vision, passion and most importantly, our mutual commitment to meet the needs and demands of our customers.
We wish him the best of luck in his new position for the benefit of our joint growth.
We are proud to inform you that our friends and cooperation partner from the German cancer research center (DKFZ) published the first study about the application of our Oxygen-17 gas with participants with glioma – Quantitative Dynamic Oxygen 17 MRI at 7.0 T for the Cerebral Oxygen Metabolism in Glioma – in the medical journal Radiology.
As part of our strategy to streamline our corporate structure and internal procedures, the management has decided to merge the activities of NUKEM Isotopes Imaging GmbH with those of NUKEM Isotopes GmbH. On this occasion, the company was merged with retroactive effect to 01.01.2019 on the NUKEM Isotopes GmbH. This step has already been certified by the notary and will be registered with the commercial register in a timely manner. We are confident that this step will further improve the service to our customers and suppliers and will contribute to more efficient fulfillment of the needs of our client orders. As a result of this operational change, customer orders for isotopes which find their application in medical technology, e.g. Oxygen-17 or Xenon-129 are again accepted directly by NUKEM Isotopes GmbH.
If you need more information on this topic, please do not hesitate to contact us anytime at email@example.com. Of course you are also welcome to contact your direct contacts.
Alzenau, Germany – It is with a mix of sadness and gratitude that the Board of Directors announces Jürgen Laucht‘s departure as Managing Director of NUKEM Isotopes GmbH.
Since 2011, Jürgen has played a critical role in the development and success of the organization and while we will miss him, we wish him the best of luck in his new challenges.
Mr. Wilhelm Plumpe will continue to serve as the companies Chief Executive Officer, while Tilo Gläser (Chief Operating Officer) and Michael Kievel (Chief Sales Officer) will take care for the operations and customer services at NUKEM Isotopes. Together with Ulf Jeschke (Chief Financial Officer) it is the companies’ priority to maintaining a stable and effective organization structure.
Again, we cannot thank Jürgen enough for the dedication, passion and enthusiasm he has given NUKEM Isotopes GmbH over the past years. Even though he decided to retire after so many years in the industry we are glad he will continue being a part of the family. Jürgen will join the advisory broad of NUKEM Isotopes.
Alzenau, Germany – NUKEM Isotopes GmbH is proud to announce and welcome Ulf Jeschke as the company’s Chief Financial Officer (CFO). Ulf will be responsible for Financial Services and Controlling at the Company and its subsidiary and will lead the bookkeeping team. During his successful career in an auditing company and in the commodity trading industry, he has gained experience as a leader of the financial group.
The whole team at NUKEM Isotopes is very excited to welcome Ulf to the NUKEM Isotopes family. He brings to us and our clients tremendous experience, knowledge and is respected throughout the industry for his honesty, integrity and accomplishments. He truly shares our vision, passion and above all, our commitment to satisfying our customers’ needs.
We have moved! In the course of our general expansion strategy, the company has decided to build a new, state of the art office building, in order to fulfil future needs. Now, after almost 12 months of intense planning- and construction work, we are very proud to announce the completion of this challenging project. With almost 1,000 m² of bright, modern offices, combined with functional storage- and packing space, we are confident, we have established a good environment for our employees in order to ensure high quality services for our valued customers.
In light of this move, our address, as well as phone numbers have changed. Our new address can be found here and our new contact information (our email addresses stay the same) can be found here (phone numbers will be updated soon).
NUKEM Isotopes GmbH and NUKEM Isotopes Imaging GmbH have successfully completed its re-certification audits, performed by BSI Group Deutschland GmbH, for the new ISO 9001:2015 quality management standard for NUKEM’s activities in trading isotopes and trading isotops for medical purposes.
As supporter for supplying high enriched Oxygen-17 (70at%) gas, we are proud to announce that the manuscript “Reproducibility of CMRO2 Determination using Dynamic 17O MRI”, submitted by the German Cancer Research Center (DKFZ) and the University of Erlangen, was accepted for publication by the journal Magnetic Resonance in Medicine. The manuscript will probably be online by end October 2017.
NUKEM Isotopes GmbH successfully completed the REACH-Registration for Li-7OH*H2O. This Registration entitles us to import more than 1t/a of Li-7OH*H2O into the European Union also after May 31st, 2018. Thus, we are perfectly prepared to cover the future Li-7 demand of our customers.
NUKEM Isotopes Imaging GmbH successfully participated at this year’s ISMRM in Honolulu. We thank all visitors for stopping by at our booth.
In cooperation with the University of Freiburg, NUKEM Isotopes Imaging GmbH carried out experiments with enriched Oxygen-17 in the form of D-Glucose. Now we are pleased to announce that the University of Freiburg got the manuscript accepted by the journal NMR in Biomedicine.
In cooperation with the University of Heidelberg and the Florida State University, NUKEM Isotopes Imaging GmbH carried out experiments to verify a new technique for detecting brain tumors with enriched Oxygen-17 in the form of D-Glucose.
NUKEM Isotopes GmbH and NUKEM Isotopes Imaging GmbH have successfully completed its surveillance audit, performed by BSI Group Deutschland GmbH. This audit has proven both companies operates a Quality Management System which complies with the requirements of ISO 9001:2008 for trading isotopes and trading isotops for medical purposes.
NUKEM Isotopes GmbH and NUKEM Isotopes Imaging GmbH launched their new website.
NUKEM Isotopes GmbH has successfully completed its re-qualification audit, performed by NUPIC member group. This audit has proven NUKEM’s management system in accordance to 10CFR50 App.B and 10CFR21. NUPIC audit team consists of professional auditior from Ameren UE, Vattenfall Ringhals Kärnkraftverk and Arizona Public Service Electric Company (APS).
NUKEM Isotopes GmbH decides to participate in Polarean, Inc. a pioneer in hyperpolarized gas technology. This stragegic decision enables NUKEM Isotopes to supply enriched Xenon-129 for lung imaging in MRT.
NUKEM Isotopes GmbH establishes reliable partnerships with gas manufacturers for the production of highly pure noble gases.